A review of human carcinogens--Part B: biological agents.

By V. Bouvard, R. Baan, K. Straif, Y. Grosse, B. Secretan, F. El Ghissassi, L. Benbrahim-Tallaa, N. Guha, Crystal Freeman, Laurent Galichet and 1 more. The Lancet Oncology, 2009

2,866 citations recorded by the source corpus.

Subfields: Oncology, Pathology and Forensic Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/5010c0f6f71157e4ec3e69c28cb99d8d14ce4096

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pathology and Forensic Medicine

In Surgery

Citations in the corpus

Human papillomavirus molecular biology and disease association (2015, background): “The detection of high-risk HPV types at other sites varies and in the oral cavity is estimated at around 5% in apparently asymptomatically infected individuals [39], rising to 50% or so in individuals with oropharyngeal cancers [40].”
Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication (2011, background): “In a recent working group at IARC, other types in the high-risk clade (HPV26, 30, 34, 53, 66, 67, 69, 70, 73, 82 and 85) were all classified for cautionary reasons as possibly carcinogenic to humans (Group 2B) even in the absence of adequate epidemiological data on their carcinogenic potential.(5,9)”
Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States (2018, background): “ered in this analysis) indirectly and through immunosuppression.(10,13) Thus, for estimates of all infections and all evaluated”
HUMAN VIRAL ONCOGENESIS: A CANCER HALLMARKS ANALYSIS (2014, background): “…and identify host and environmental cofactors contributing to full development of malignancy for each of the major human viruses defined in the last IARC report as Group 1 Biological carcinogenic agents for which there is “sufficient evidence of carcinogenicity in humans” (Bouvard et al., 2009).”
An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening. (2019, methodology): “We defined positivity as detection of one of 13 high-risk HPV per the International Agency For Research On Cancer classification (26).”
Evidence for single-dose protection by the bivalent HPV vaccine—review of the Costa Rica HPV Vaccine Trial and future research studies (2018, background): “HPV vaccines were licensed and recommended a decade ago [4], in order to reduce individual-and population-prevalence of HPV, a necessary cause of cervical carcinogenesis [5].”
Human papillomavirus types in 115,789 HPV‐positive women: A meta‐analysis from cervical infection to cancer (2012, background): “Nevertheless, it is recognized that individual HR types differ enormously in their relative carcinogenic potential.(1) Thus, new screening tests are emerging to provide some degree of genotyping with the aim to improve risk stratification among HPV-positive subjects and to allow adapted follow-up pr”
Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand? (2017, background): “Human Papillomavirus (HPV)-driven oropharyngeal squamous cell carcinoma (OPSCCs) represent a distinct disease from other head and neck squamous cell carcinomas (HNSCC) that are traditionally induced by excessive tobacco and alcohol consumption [1].”
Global cancer statistics (2011, background): “The exact causes for this increase are not entirely clear but could be related to altered immune function associated with older age as well as HCV infection, which is prevalent among older Egyptians and has recently been classified by the IARC as having a causal link to NHL.(124,125)”